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Abstract Neutrophil elastase (NE) upregulates the fibrinogen
binding activity of the platelet integrin KIIbL3 through proteolysis
of the KIIb subunit. This cleavage allows a strong potentiation of
platelet aggregation induced by low concentrations of cathepsin
G (CG), another neutrophil serine proteinase. During this
activation process, we observed a strong fibrinogen binding and
aggregation-dependent phosphatidylinositol 3,4-bis-phosphate
(PtdIns(3,4)P2) accumulation. PtdIns(3,4)P2 has been suggested
to play a role in the stabilization of platelet aggregation, possibly
through the control of a maintained KIIbL3 integrin activation.
Here we show that inhibition of phosphoinositide 3-kinase (PI 3-
K) by very low concentrations of wortmannin or LY294002
transformed the irreversible platelet aggregation induced by a
combination of NE and low concentrations of CG into a
reversible aggregation. However, although inhibition of PI 3-K
was very efficient in inducing platelet disaggregation, it did not
modify the level of KIIbL3 activation as assessed by binding of an
activation-dependent antibody. These results indicate that PI 3-K
activity can control the irreversibility of platelet aggregation
even under conditions where KIIbL3 integrin remains
activated. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.




We have previously characterized the molecular mecha-
nisms underlying the synergistic activation of platelets by
the secretable neutrophil serine proteinases elastase (NE)
and cathepsin G (CG), which have been established as major
mediators for the activation of platelets by neutrophils [1]. At
concentrations v500 nM, CG is a potent platelet agonist, and
triggers cell responses similar to those observed with thrombin
[2]. As thrombin, CG is a serine proteinase which can potently
stimulate platelets through structurally related proteinase-ac-
tivated receptors (PAR) [3,4]. It was recently demonstrated
that activation by CG is speci¢cally mediated by the PAR4
receptor in human platelets [5], while thrombin can activate
both PAR1 and PAR4 receptors [6]. At low concentrations
(6 200 nM), CG induces a weak aggregation which is
strongly enhanced by NE, although NE by itself does not
activate human platelets [7]. This cooperation between the
two proteinases requires a peculiar NE-dependent upregula-
tion of the ¢brinogen binding capacity of KIIbL3 integrin, the
¢brinogen receptor which supports platelet aggregation,
through proteolysis of the carboxyl-terminus of the KIIb sub-
unit heavy chain. Thus, while low CG initiates mandatory
intracellular signalling, insu⁄cient by itself to promote a
strong and stable aggregation, NE triggers a spatial reorien-
tation of the extracellular domains of KIIbL3 integrin allowing
an increased binding of ¢brinogen. Since more ¢brinogen
binds and cross-links adjacent platelets, post-occupancy ‘out-
side-in’ signalling events through KIIbL3 may amplify cell ac-
tivation initiated by low CG and ¢nally maximize the recruit-
ment of platelets into stable aggregates, apparently similar to
those produced by higher concentrations of CG or other
strong platelet agonists [8].
Considering the singular role of the post-KIIbL3 occupancy
signalling in the robust aggregation produced by the combi-
nation of NE and low CG, this model may be useful to better
understand the close relationship between KIIbL3 engagement
and the phosphatidylinositol 3,4-bis-phosphate (PtdIns(3,4)P2
accumulation described in several studies [9^13]. Indeed,
PtdIns(3,4)P2 accumulates in an aggregation-dependent man-
ner and a large part of its synthesis requires the engagement
of KIIbL3 integrin. Moreover, a phosphoinositide 3-kinase (PI
3-K) and its product PtdIns(3,4)P2 have been shown to play
an important role in the stabilization of the irreversible plate-
let aggregation induced by the thrombin receptor PAR1 acti-
vating peptide (TRAP) [14,15]. PI 3-K inhibition by wortman-
nin or LY294002 does not impair granule secretion but leads
to a reversible platelet aggregation. Upon addition of TRAP,
the synthesis of phosphatidylinositol 3,4,5-tris-phosphate
(PtdIns(3,4,5)P3), another product of PI 3-K activation, is
rapid and transient whereas PtdIns(3,4)P2 accumulates slowly.
By adding PI 3-K inhibitors 2 min after platelet stimulation
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by TRAP [15], when aggregation and PtdIns(3,4)P2 produc-
tion are at their maximum and PtdIns(3,4,5)P3 is returned to
its basal level, it was further shown that PtdIns(3,4)P2 rapidly
disappears and desaggregation occurs. As PI 3-K inhibition
leads to a reversion of KIIbL3 from its activated conformation
into a resting state in TRAP-stimulated platelets [14], it was
suggested that PtdIns(3,4)P2 plays a role in maintaining KIIbL3
in an activated state, which in turn allows stable aggregates to
form. Supporting the role of PtdIns(3,4)P2 in the stabilization
of aggregation, ADP, added to a suspension of washed plate-
lets in the presence of exogenous ¢brinogen, is not able to
induce a sustained synthesis of PtdIns(3,4)P2 and is only
able to induce a reversible platelet aggregation [16]. This spon-
taneous disaggregation is accompanied by the reversal of the
KIIbL3 integrin from its activated conformation, as indicated
by the release of platelet-bound ¢brinogen [17].
Using NE and CG separately or in combination, the
present study identi¢es an original experimental model in
which PI 3-K was strictly required for the irreversibility of
platelet aggregation without a¡ecting the sustained KIIbL3 in-
tegrin activation. Since PtdIns(3,4)P2 but not PtdIns(3,4,5)P3
markedly accumulated upon activation by the combination of
NE and low concentrations of CG, these observations unravel
a new mechanism in the formation of stable aggregates de-
pending directly on PtdIns(3,4)P2 synthesis downstream of
KIIbL3.
2. Materials and methods
2.1. Materials
The mAb PAC-1 (IgM) [18] and AP-2 (IgG1) [19] were provided by
the University Cell Center of Pennsylvania (Philadelphia, PA, USA)
and by Dr. T.J. Kunicki (Scripps Research Institute, La Jolla, CA,
USA), respectively. Non-speci¢c murine monoclonal IgG1 or IgM
were obtained from DAKO (Glostrup, Denmark).
[32P]Orthophosphate was from Amersham International (Little Chal-
font, UK). TLC plates were from Merck (Darmstadt, Germany). The
TRAP peptide was purchased from Bachem (Bubendorf, Switzerland).
Human thrombin was from Ho¡man-La Roche (Basel, Switzerland).
Human leucocyte CG and NE were puri¢ed using a two-step chro-
matographic procedure as previously described [7]. Fibrinogen was
purchased from Kabi (Stockholm, Sweden). The PI 3-K inhibitors
LY294002 and wortmannin were from Biomol Research Laboratories
(Plymouth Meeting, PA, USA). Eglin C was provided by Dr. H.P.
Schnebli (Ciba-Geigy Research, Basel, Switzerland). All other re-
agents were obtained as indicated in [8].
2.2. Isolation and labelling of platelets
Human blood platelets were prepared essentially as described pre-
viously [8]. For inositol lipid analysis, platelets were labelled with 0.5
mCi/ml of [32P]orthophosphate during 60 min in a phosphate-free
Tyrode’s bu¡er (137 mM NaCl; 2.68 mM KCl; 11.9 mM NaHCO3 ;
0.42 mM NaH2PO4 ; 2 mM CaCl2 ; 1 mM MgCl2 ; 5.5 mM glucose;
5 mM HEPES), pH 6.5, at 37‡C. 32P-labelled platelets were then washed
once in the same bu¡er and ¢nally resuspended at a ¢nal concentra-
tion of 4U108 platelets/ml in Tyrode’s bu¡er, pH 7.4, supplemented
with 0.35% (w/v) BSA. The entire procedure was performed at 37‡C
and isolated platelets were maintained at this temperature until use.
2.3. Aggregation measurements
Platelet aggregation in 0.5 ml aliquots was monitored at 37‡C using
a Dual aggrometer (Chrono-Log corp., Havertown, PA, USA) under
constant stirring (1 100 rpm). When required, samples were preincu-
bated with various concentrations of LY294002 or wortmannin for
5 and 15 min, respectively, or in the presence of inhibitor vehicle alone
(0.2% (v/v) dimethylsulfoxide). Fibrinogen (0.7 mg/ml) was added
2 min before stimulation, which was initiated by addition of 550 nM
CG, or a threshold concentration of CG (tCG), or the combination of
tCG preceded for 10 s by 400 nM NE. For each tested platelet sus-
pension, tCG was determined as the concentration of enzyme result-
ing in platelet shape change followed by a 10^15% increase in light
transmission within 3 min of stirring. This concentration was always
in the range 110^160 nM.
2.4. Lipid extraction and analysis
Aggregations were stopped at given time points by addition of
chloroform/methanol (1/1, v/v) containing 0.4 N HCl and lipids
were immediately extracted following the modi¢ed procedure of Bligh
and Dyer [20]. For [32P]PtdIns(3,4)P2 and [32P]PtdIns(3,4,5)P3 quan-
ti¢cation, lipids were ¢rst resolved by TLC using chloroform/acetone/
methanol/acetic acid/water (80/30/26/24/14, v/v). The spots corre-
sponding to PtdIns(3,4)P2 and PtdIns(3,4,5)P3 were then scraped
o¡, deacylated by 20% methylamine and analyzed by HPLC on a
Whatman Partisphere strong ion exchange column, as previously de-
scribed [21].
Fig. 1. Synthesis of 3-phosphoinositides in platelets exposed to NE
and/or CG. A, B: Suspensions of 32P-labelled platelets, stirred at
37‡C, were preincubated for 2 min with 0.7 mg/ml ¢brinogen before
stimulation for 2 min with 400 nM NE, tCG (110^160 nM) alone
or in combination with NE (NE/tCG), or 550 nM CG. Control
platelets (C) were incubated non-activated. Cell lipids were extracted
and [32P]PtdIns(3,4)P2 and [32P]PtdIns(3,4,5)P3 quanti¢ed as indi-
cated in Section 2. C: Kinetics of [32P]PtdIns(3,4)P2 (¢lled circles)
and [32P]PtdIns(3,4,5)P3 (open circles) accumulation were deter-
mined in platelets stimulated by the combination of NE and tCG.
Results, expressed as the fold increase of the lipid accumulation rel-
ative to the control non-activated platelets, are the mean þ S.E.M.
of three to ¢ve experiments conducted with cells from di¡erent do-
nors. *P6 0.O5; **P6 0.01 (Student’s t-test for paired samples).
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2.5. Flow cytometry analysis
Platelet samples were treated as for aggregation analysis except that
exogenous ¢brinogen was omitted as this natural ligand of the acti-
vated KIIbL3 integrin may competitively inhibit the binding of the
mAb PAC-1 [18]. In any case, once the agonist has been added
(NE, tCG, or NE/tCG as indicated above, or 0.5 U/ml human throm-
bin, or 7.5 WM TRAP), the stirring was allowed for only 5 s in order
to homogenize the milieu, then samples were incubated for 3 min at
37‡C undisturbed in order to prevent platelet aggregate formation.
The reaction was stopped by the addition of 40 Wg/ml (5 WM) eglin
C, an inhibitor of CG and NE [22] and 2 mM phenylmethylsulfonyl
£uoride. Platelets were then immediately ¢xed with 1% (v/v) form-
aldehyde for 30 min at room temperature. Following the ¢xation,
samples were diluted 10-fold in Tyrode’s medium containing 0.35%
BSA and then incubated for 30 min at 4‡C with saturating concen-
trations of puri¢ed PAC-1 (2 Wg/ml), AP-2 (1 Wg/ml), or with murine
IgG1 or IgM as control isotypes. Subsequent incubations, including
that with the corresponding secondary £uorescein isothiocyanate-la-
belled antibody, and cytometric analysis using a FACScan £ow cy-
tometer (Becton Dickinson, Mountain View, CA, USA) were as pre-
viously described [8]. The median of £uorescence intensity (MFI) of
the cell population was used to measure the PAC-1 or AP-2 epitope
expression on the KIIbL3 integrin, the MFI obtained with control iso-
type immunoglobulins being subtracted in all cases.
3. Results
Exposure of platelets to 400 nM NE did not induce PI 3-K
activation, as measured through PtdIns(3,4)P2 and
PtdIns(3,4,5)P3 production (Fig. 1A,B). Stimulation of plate-
lets with threshold concentrations of CG (tCG) induced a
slight but signi¢cant production of PtdIns(3,4)P2 but no sig-
ni¢cant synthesis of PtdIns(3,4,5)P3 (Fig. 1A,B). Conversely,
addition of tCG following NE treatment clearly led to a
strong production of PtdIns(3,4)P2 (Fig. 1A) whereas the syn-
thesis of PtdIns(3,4,5)P3 remained modest at any time point
investigated (Fig. 1C). PtdIns(3,4)P2 started to accumulate
signi¢cantly 1 min following addition of tCG (Fig. 1C), which
appears rather late if compared to the kinetics previously ob-
served in TRAP-stimulated platelets [15]. This production of
PtdIns(3,4)P2 was strictly dependent upon the presence of
exogenous ¢brinogen and stirring of platelets, i.e. the aggre-
gation of platelets (data not shown). Finally, a fully activating
concentration of CG induced an important accumulation of
PtdIns(3,4)P2 (Fig. 1A) comparable to that induced by throm-
bin (not shown). No signi¢cant increase in PtdIns3P was ob-
served under our experimental conditions.
As previously established [7,8], platelet suspensions stirred
for 3 min with 400 nM NE did not show any functional
responses (not shown). CG in the range 110^160 nM (tCG)
induced a limited but signi¢cant reversible platelet aggrega-
tion, with 10^15% increase in light transmission at the max-
imum of aggregate formation (Fig. 2A,B). Addition of NE 10
s before tCG resulted in a potent aggregation, similar to that
induced by an optimal concentration of CG (550 nM, Fig.
2C) or 0.5 IU/ml thrombin (not shown). However, this aggre-
gation required addition of exogenous ¢brinogen since gran-
ule exocytosis, and thus, surface expression of endogenous
pro-aggregatory adhesive proteins [23], induced by the combi-
nation of NE and tCG is limited [8]. To test whether PI 3-K
would be involved in the mechanisms supporting the aggrega-
tion induced by the combination of NE and tCG, we used the
two unrelated inhibitors of this lipid kinase, LY294002 and
wortmannin, at low concentrations. As shown in Fig. 2, LY
294002 (95 WM) or wortmannin (910 nM) had no signi¢cant
e¡ect on the pattern of CG-induced platelet aggregation, ei-
ther at a threshold or a high concentration of the proteinase.
Conversely, challenge of platelets with the combination of NE
and tCG, in the presence of PI 3-K inhibitors, resulted in a
marked and rapid reversibility of the aggregation process
without signi¢cant changes in the initial velocity and maximal
intensity of aggregation (Fig. 2A,B).
These results led us to investigate the activation state of
KIIbL3 by using PAC-1, an IgM monoclonal antibody acting
as a ¢brinogen-like ligand for activated KIIbL3 [18], and £ow
cytometry analysis. As previously observed, when using
Fig. 2. E¡ects of low concentrations of PI 3-K inhibitors on the irreversible platelet aggregation induced by the combination of NE and CG.
Platelet aggregation was measured as described in Section 2. A, B: Platelet suspensions were preincubated with various concentrations of the
two PI 3-K inhibitors, LY294002 (LY, A) or wortmannin (Wort, B), as indicated. They were then stimulated, in the presence of 0.7 mg/ml ¢-
brinogen, with a tCG of 150 nM, either alone or preceded for 10 s by 400 nM NE. C: Aggregation was induced by a fully activating concen-
tration of CG (550 nM) in the absence or presence of 5 WM LY294002 or 10 nM wortmannin. Tracings show the time course of the variation
in light transmission (vLT) in the cell suspensions, and are representative of at least three experiments performed with platelets from di¡erent
individuals.
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TRAP (7.5 WM) as the platelet agonist [14], we found that the
reversion of aggregation induced by wortmannin treatment
was accompanied by an inhibition of the sustained activation
of KIIbL3 (45.4 þ 12.5% of the control, n = 3) (Fig. 3A). This
inhibition was not due to an impaired translocation of the
intracellular pool of KIIbL3 to the plasma membrane following
TRAP activation [14], as measured with AP-2, an KIIbL3 com-
plex-speci¢c antibody reacting with both the resting and active
forms of the receptor (Fig. 3B). It is noteworthy that PI 3-K
inhibition did not change signi¢cantly the platelet aggregation
induced by 0.5 IU/ml thrombin (not shown) and did not a¡ect
the activation of KIIbL3 induced by this concentration of
thrombin (Fig. 3A). When initiated by NE or tCG taken
separately or, more interestingly, in combination, the level
of KIIbL3 activation and surface expression remained unaf-
fected upon treatment with 50 nM wortmannin (Fig. 3A,B),
a concentration that fully inhibited D3-phosphoinositide syn-
thesis and reversed platelet aggregation (not shown).
These data suggest a new mechanism through which PI 3-K
and its product PtdIns(3,4)P2 stabilize platelet aggregates
downstream of KIIbL3:
4. Discussion
The aim of the present study was to investigate the putative
role of the PI 3-K-dependent signalling pathway in the syner-
gistic activation of human platelets by the neutrophil protein-
ases NE and CG. The speci¢c proteolytic activation of the
KIIbL3 integrin and subsequent binding of ¢brinogen induced
by NE alone fail to initiate a signi¢cant platelet activation and
aggregation [8] and did not induce PI 3-K activation. Thus,
the peculiar upregulation of the ¢brinogen receptor by a direct
extracellular proteolytic processing of one of its subunits is
not su⁄cient per se to induce any of the signalling pathways
investigated until now. This is di¡erent from what is observed
when activation of KIIbL3 is promoted by the binding of acti-
vating antibodies to the integrin [12,14,24] which is an useful
model to investigate biochemical events downstream of KIIbL3.
With this model, Ban¢c et al. [12] have proposed a new mech-
anism leading to PtdIns(3,4)P2 synthesis independently of
PtdIns(3,4,5)P3 production. This pathway involves the
HsC2-PI 3-K generating PtdIns3P, subsequently metabolized
into PtdIns(3,4)P2 by a PtdIns(3)P 4-kinase [13].
When KIIbL3 activation is the result of the proteolysis by
NE combined with an ‘inside-out’ signalling initiated by a low
concentration of CG, a potent accumulation of PtdIns(3,4)P2
was observed, with only a minute increase in PtdIns(3,4,5)P3.
Since the potentiation between NE and CG occurred without
marked granule exocytosis [8], the PtdIns(3,4)P2 synthesis re-
quired the presence of exogenous ¢brinogen and was relatively
delayed, starting only 1 min after addition of the stimuli.
Although we could not observe any increase of PtdIns(3)P,
these results support the involvement of HsC2-PI 3-K since no
signi¢cant formation of PtdIns(3,4,5)P3 could be observed.
Interestingly, we found that the irreversible platelet aggre-
gation occurring upon stimulation by the combination of NE
and CG was strictly dependent on PI 3-K activation and
PtdIns(3,4)P2 production. Indeed, low concentrations of wort-
mannin or LY294002 (5 nM and 2.5 WM, respectively) re-
sulted in the formation of unstable aggregates. As a compar-
ison, higher doses of wortmannin (v50 nM) are required to
reverse the platelet aggregation induced by TRAP [14,21]. Ac-
cording to the primary agonist used and the signal transduc-
tion pathway implicated, several mechanisms may control the
stabilization of platelet aggregation. The PI 3-K-dependent
pathway appears to be mandatory for a number of agonists
(C.T, M.P and B.P., unpublished observations) but not all
since platelet aggregation induced by high concentrations of
thrombin is una¡ected by PI 3-K inhibition. One of the PI 3-
K-dependent mechanisms that might control the stability of
aggregation is the maintenance of a sustained high a⁄nity of
KIIbL3 towards ¢brinogen. Indeed, in agreement with Kovac-
sovics et al. [14], we also measured a decrease in PAC-1 bind-
ing to KIIbL3 when TRAP-stimulated platelets are pretreated
by wortmannin without changes in the surface expression of
this integrin. However, our results suggest that PtdIns(3,4)P2
might actually stabilize aggregates by another mechanism
since, although platelet aggregation induced by the combina-
tion of NE and CG became reversible, PAC-1 binding was
una¡ected by PI 3-K inhibition. Thus, blocking the PI 3-K
pathway may result in platelet disaggregation without inhibi-
tion of the major platelet aggregation receptors.
Our previous studies have shown that wortmannin-induced
disaggregation of TRAP-stimulated platelets parallels a reor-
ganization of the cytoskeleton, with a rapid destabilization of
F-actin-associated signalling complexes and a speci¢c release
of the contractile protein myosin [15]. Whether speci¢c
Fig. 3. E¡ects of wortmannin on the redistribution and activation
of the KIIbL3 integrin induced by the combination of NE and tCG.
Unstirred platelet suspensions were preincubated with 50 nM wort-
mannin (+Wort) or with vehicle alone (0.2% DMSO, 3Wort) for
15 min at 37‡C in the absence of exogenous ¢brinogen. Cell activa-
tion was initiated by adding 400 nM NE, tCG (150^180 nM) alone
or in combination with NE (NE/tCG), 0.5 IU/ml thrombin, or 7.5
WM TRAP, and followed for 3 min. Proteinases were blocked with
eglin C and PMSF. Binding of PAC-1 (A, activation of KIIbL3) and
AP-2 (B, redistribution of KIIbL3) antibodies to platelets was then
measured by £ow cytometry as described in Section 2. Results, ex-
pressed as the fold increase of the MFI relative to the control non-
activated platelets (C), are the mean þ S.E.M. of three or four ex-
periments conducted with cells from di¡erent donors.
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changes in the cytoskeleton dynamic induced by PI 3-K inhi-
bition are responsible for the disaggregation observed here
remains to be established. We propose that the present model
of KIIbL3 activation might be particularly useful to identify
direct e¡ectors of PtdIns(3,4)P2 involved in the strengthening
of platelet aggregation and by this way, new potential phar-
macological targets in order to modulate irreversible aggrega-
tion.
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